Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Dec;66(6):1177–1179. doi: 10.1038/bjc.1992.431

Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma.

R A Janssen 1, D T Sleijfer 1, A A Heijn 1, N H Mulder 1, T H The 1, L de Leij 1
PMCID: PMC1978045  PMID: 1457361

Abstract

The phenotype of peripheral blood lymphocytes of 27 renal cell carcinoma patients before and at the end of subcutaneously given rIL-2 therapy was determined by two colour flow cytometry. Therapy induced changes in peripheral blood leucocyte composition and phenotypes were comparable to those reported for intravenously given rIL-2. The present paper shows a correlation between the 'activation status' of the patient before therapy and eventual response.

Full text

PDF
1177

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ellis T. M., Creekmore S. P., McMannis J. D., Braun D. P., Harris J. A., Fisher R. I. Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2. Cancer Res. 1988 Nov 15;48(22):6597–6602. [PubMed] [Google Scholar]
  2. Favrot M. C., Combaret V., Negrier S., Philip I., Thiesse P., Freydel C., Bijmann J. T., Franks C. R., Mercatello A., Philip T. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma. J Biol Response Mod. 1990 Apr;9(2):167–177. [PubMed] [Google Scholar]
  3. Lotze M. T., Custer M. C., Sharrow S. O., Rubin L. A., Nelson D. L., Rosenberg S. A. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res. 1987 Apr 15;47(8):2188–2195. [PubMed] [Google Scholar]
  4. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  5. Sleijfer D. T., Janssen R. A., Buter J., de Vries E. G., Willemse P. H., Mulder N. H. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol. 1992 Jul;10(7):1119–1123. doi: 10.1200/JCO.1992.10.7.1119. [DOI] [PubMed] [Google Scholar]
  6. Sleijfer D. T., Janssen R. A., Willemse P. H., Martens A., de Leij L., de Vries E. G., Mulder N. H. Low-dose regimen of interleukin-2 for metastatic renal carcinoma. Lancet. 1990 Jun 23;335(8704):1522–1523. doi: 10.1016/0140-6736(90)93057-v. [DOI] [PubMed] [Google Scholar]
  7. Sondel P. M., Kohler P. C., Hank J. A., Moore K. H., Rosenthal N. S., Sosman J. A., Bechhofer R., Storer B. Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res. 1988 May 1;48(9):2561–2567. [PubMed] [Google Scholar]
  8. Urba W. J., Steis R. G., Longo D. L., Kopp W. C., Maluish A. E., Marcon L., Nelson D. L., Stevenson H. C., Clark J. W. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. Cancer Res. 1990 Jan 1;50(1):185–192. [PubMed] [Google Scholar]
  9. Weil-Hillman G., Fisch P., Prieve A. F., Sosman J. A., Hank J. A., Sondel P. M. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. Cancer Res. 1989 Jul 1;49(13):3680–3688. [PubMed] [Google Scholar]
  10. West W. H. Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies. Cancer Treat Rev. 1989 Jun;16 (Suppl A):83–89. doi: 10.1016/0305-7372(89)90027-3. [DOI] [PubMed] [Google Scholar]
  11. West W. H., Tauer K. W., Yannelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987 Apr 9;316(15):898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES